[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.197.90.95. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Article
November 1957

Aminoacetic Acid (Glycine) as an Antifibrillary Agent in Hypothermia

Author Affiliations

Dallas, Texas; Seattle
From the Arctic Aeromedical Laboratory, Department of Physiology, APO 731, Seattle. Dr. Beavers formerly Captain, Medical Corp, United States Air Force.

AMA Arch Surg. 1957;75(5):776-779. doi:10.1001/archsurg.1957.01280170086039
Abstract

The chief hazard in the use of hypothermic anesthesia continues to be the occurrence of ventricular fibrillation. In order to avoid this complication, the level of hypothermia induced during surgical procedures is usually restricted to rectal temperatures above 28 C (82.4 F). The advantages of hypothermia in surgery increase, however, in proportion to the lowering of temperature. In an effort to control fibrillation at low temperatures, the antiarrhythmic effects of many pharmacological agents have been investigated,1,2 but few have been found wholly satisfactory.

Aminoacetic acid U. S. P. (Glycine), an amino acid, has been reported to suppress cyclopropane-epinephrine-induced arrhythmias.3 In a previous study,4 intravenous aminoacetic acid was shown to be easily administered, safe, and well tolerated by hypothermic animals. The present investigation was initiated, therefore, to evaluate the use of intravenous aminoacetic acid as a means of preventing ventricular fibrillation during hypothermia, with and without the added

First Page Preview View Large
First page PDF preview
First page PDF preview
×